Roche’s Phase III CELESTIMO study for Lunsumio (mosunetuzumab) met its primary endpoint.
The trial evaluated Lunsumio combined with lenalidomide for patients with relapsed or refractory follicular lymphoma who received at least one prior line of treatment.
Results showed a statistically significant and clinically meaningful improvement in progression-free survival.
The combination's safety profile remained consistent with individual drugs, identifying no new safety concerns.
Roche will submit this data to health authorities and present findings at an upcoming medical meeting.
Overall survival data remained immature at the time of this interim analysis.